Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CANbridge Pharmaceuticals Inc. ( (HK:1228) ) has provided an announcement.
CANbridge Pharmaceuticals Inc. has entered into a strategic collaboration and exclusive commercial services agreement with a subsidiary of Qingdao Baheal Medical Inc. This agreement appoints Baheal as the exclusive Contract Sales Organization for promoting CANbridge’s products in mainland China, Hong Kong, and Macau. The agreement, which is of a revenue nature and part of the company’s ordinary business activities, does not constitute a notifiable or connected transaction under Hong Kong’s listing rules. This strategic move is expected to enhance CANbridge’s market presence in the Greater China region.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative therapies for rare diseases and targeted cancers. The company operates primarily in the Greater China region, including mainland China, Hong Kong, and Macau.
Average Trading Volume: 11,921,847
Technical Sentiment Signal: Buy
Current Market Cap: HK$709.5M
For an in-depth examination of 1228 stock, go to TipRanks’ Overview page.